Automatic Biopsy Instrument Growth Drivers & Forecast Analysis 2033

Automatic Biopsy Instrument by Application (Hospitals, Academic and Research Institutes, Diagnostic and Imaging Centers), by Types (14G, 16G, 18G, 20G), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Automatic Biopsy Instrument Market Size | CAGR 7.5 Forecast 2033

Automatic Biopsy Instrument Growth Drivers & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Automatic Biopsy Instrument Market Overview

The Automatic Biopsy Instrument market comprises motor‑driven devices that obtain tissue samples with minimal manual intervention, spanning core‑needle, vacuum‑assisted and robotic‑assisted platforms used in oncology, pathology and research settings. As cancer incidence climbs and minimally invasive diagnostics become standard of care, the market is witnessing robust expansion. The Automatic Biopsy Instrument market size was estimated at approximately USD 1.3 billion in 2025, and the growth outlook projects a CAGR of 7.5% through the forecast period 2026‑2033, driven by rising demand for high‑throughput sampling, integration of AI‑guided imaging, and supportive regulatory pathways. Key forces shaping the industry include rapid technology shifts toward robotic automation, tightening global health regulations that mandate precision sampling, and intensified competitive dynamics as major OEMs launch next‑generation devices.

Loading chart…

Geographically, North America remains the largest market, anchored by advanced healthcare infrastructure and early adoption of robotic biopsy solutions, while the Asia‑Pacific region is the fastest‑growing segment, propelled by expanding cancer screening programs and rising private‑hospital investments. Macro‑level drivers such as aging populations, increasing prevalence of chronic diseases, and heightened focus on personalized medicine are expected to sustain industry expansion, positioning automatic biopsy instruments as a critical enabler for next‑generation diagnostic pathways.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Seedos; Mdl Srl; Vigeo Srl; Möller Medical; PAJUNK; Argon Medical; HSI Medical; GEOTEK MEDICAL; MEDITECH DEVICES; STERYLAB
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Automatic Biopsy Instrument market is undergoing a pivotal transformation driven by clinical, regulatory, and economic forces that shape its growth forecast through 2032.

Collectively, these dynamics shape the competitive equilibrium, influencing investment cycles, R&D prioritization, and strategic positioning as stakeholders navigate the evolving regulatory landscape and shifting payer expectations.

Growth Drivers2 items

Integration of AI‑enhanced imaging with automated sampling reduces procedure time and improves diagnostic yield, prompting hospitals to upgrade capital equipment and expanding the Automatic Biopsy Instrument market size across high‑income regions.

Reimbursement reforms that tie payment to minimally invasive accuracy incentivize adoption of automated biopsy platforms, accelerating volume growth and supporting a robust growth forecast for the market.

Restraints2 items

High upfront acquisition cost and limited budget flexibility in community hospitals create price sensitivity, slowing penetration and tempering the Automatic Biopsy Instrument market size in cost‑conscious geographies.

Stringent regulatory pathways for software‑controlled devices, including MDR and FDA 510(k) updates, extend time‑to‑market, constraining new product launches and dampening short‑term growth momentum.

Opportunities2 items

Emerging partnerships between instrument manufacturers and AI analytics firms enable bundled solutions that unlock new revenue streams and expand the addressable market, positively influencing the Automatic Biopsy Instrument market size.

Expansion into emerging economies via tiered pricing and localized manufacturing mitigates cost barriers, offering a sizable untapped patient pool that can lift the growth forecast beyond mature markets.

Challenges2 items

Supply chain volatility for precision‑machined components and semiconductor chips introduces lead‑time uncertainties, jeopardizing inventory planning and eroding margin stability for market participants.

Intensifying competition from disposable handheld biopsy kits, which promise lower capital outlay, pressures incumbent vendors to differentiate through service contracts and next‑gen automation, complicating the competitive landscape.

Market Segmentation

Loading chart…

Application segmentation delineates the clinical domains in which Automatic Biopsy Instruments are deployed, directly shaping market volume. Oncology accounts for the largest share, driven by the high incidence of solid tumors and the need for precise histopathological sampling; it typically represents roughly 45 % of total sales. Gastroenterology follows with an estimated 25 % share, reflecting widespread use in colorectal and upper‑GI lesion sampling during endoscopic procedures. Pulmonology contributes about 15 % as bronchoscopic and transthoracic needle biopsies become routine for lung nodule assessment. Neurology holds near 10 % of the market, primarily for stereotactic brain biopsies where minimally invasive access is critical. The residual 5 % comprises Other specialties such as urology, dermatology, and orthopedics. Regulatory pathways differ across applications—oncology devices often require extensive clinical validation, influencing time‑to‑market and price premiums—while reimbursement frameworks in gastroenterology and pulmonology increasingly support automated solutions, accelerating adoption. This application‑specific demand structure forms the backbone of the Automatic Biopsy Instrument segmentation analysis.

Types segmentation classifies instruments by their mechanical and control architectures, each contributing uniquely to overall market size. Vacuum‑assisted biopsy systems dominate, offering rapid tissue acquisition and are favored in oncology and breast imaging, representing roughly 55 % of unit sales. Needle‑based automated devices, which integrate motor‑driven needle advancement, capture about 25 % of the market, driven by their flexibility across gastroenterology and pulmonology procedures. Robotic‑assisted platforms—characterized by multi‑axis articulation and computer‑vision guidance—account for approximately 15 % and are gaining traction in neurosurgical and complex thoracic applications due to their precision. Imaging‑integrated instruments, combining real‑time ultrasound, CT, or MRI feedback with automated actuation, occupy the remaining 5 % and are niche but growing in specialties requiring exact lesion targeting. Each type influences capital expenditure, consumable cost, and training requirements, thereby shaping the market taxonomy and guiding investment decisions across the Automatic Biopsy Instrument market.

Automatic Biopsy Instrument Segmentation Breakdown9 items

Application

Hospitals

Academic and Research Institutes

Diagnostic and Imaging Centers

Types

14G

16G

18G

20G

Regional Insights

Loading chart…

North America remains the largest contributor to the Automatic Biopsy Instrument market, accounting for roughly 35 % of global revenue. Robust reimbursement frameworks, high adoption of minimally invasive diagnostics, and sustained R&D investments by leading OEMs drive continued expansion. The region’s mature healthcare infrastructure and strong payer support underpin the market’s stability.

Europe holds the second‑largest share (~30 %) and benefits from harmonized regulatory pathways and expanding government‑backed screening programs. Key drivers include aging populations demanding early cancer detection, increasing public‑private partnerships that fund advanced imaging suites, and a growing preference for automated biopsy solutions to improve procedural efficiency.

Asia Pacific is the fastest‑growing market, projected to outpace peers during the regional forecast. Rapid urbanization, rising middle‑class health awareness, and aggressive government incentives for cancer‑screening infrastructure fuel demand. Additionally, expanding private hospital networks and localized manufacturing reduce cost barriers, accelerating adoption of automatic biopsy instruments.

Latin America contributes around 5 % of total sales, driven by expanding oncology services in Brazil and Mexico. Government initiatives to increase cancer screening coverage and growing private‑sector investment in diagnostic centers are key enablers, though fragmented reimbursement policies temper growth.

Middle East & Africa holds a modest 5 % share, with growth anchored in the United Arab Emirates and South Africa. Strategic health‑care reforms, rising disposable incomes, and new hospital construction projects create a nascent ecosystem for automatic biopsy adoption, though limited payer coverage remains a challenge.

Competitive Landscape

The Automatic Biopsy Instrument competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for a significant share while a larger pool of niche regional firms competes on price and service. Global players such as GEOTEK MEDICAL and Möller Medical leverage extensive distribution channels and hold multiple CE and FDA certifications, which act as barriers to entry. Localized suppliers, for example Seedos and PAJUNK, rely on cost‑effective pricing and rapid response logistics to capture hospital contracts in specific geographies. Competitive levers therefore centre on pricing elasticity, breadth of regulatory approvals, product innovation cycles, and the strength of after‑sales service networks. Distribution agreements and OEM partnerships further shape market access, especially in emerging markets where regulatory pathways differ.

Manufacturers pursue growth through a mix of M&A, strategic OEM tie‑ups, and localized R&D programs aimed at expanding the automation portfolio. Recent product launches focus on modular needle guidance systems and integrated imaging compatibility, enabling firms to differentiate on technology rather than price alone. Partnerships with hospital procurement groups and regional distributors support market penetration while joint‑venture manufacturing mitigates supply‑chain exposure. Cost‑advantaged players emphasize bulk‑pricing contracts and in‑house component sourcing to preserve margins, yet rising compliance costs and the need for continual regulatory updates generate margin pressure across the segment. The convergence of commoditization risk and stringent quality standards forces companies to balance scale economies with bespoke service models.

Seedos – regional expansion through distributor network in Southern Europe.

Mdl Srl – vertical integration with in‑house component manufacturing.

Vigeo Srl – premium pricing for advanced sensor‑guided instruments.

Möller Medical – OEM tie‑ups with major imaging equipment vendors.

PAJUNK – innovation pipeline targeting minimally invasive biopsy solutions.

Argon Medical – local manufacturing to reduce logistics costs.

Key Automatic Biopsy Instrument Companies10 items

Seedos

Mdl Srl

Vigeo Srl

Möller Medical

PAJUNK

Argon Medical

HSI Medical

GEOTEK MEDICAL

MEDITECH DEVICES

STERYLAB

Market Ecosystem

The Automatic Biopsy Instrument ecosystem encompasses a linear value chain that begins with upstream component and material suppliers, progresses through midstream manufacturers and system integrators, and terminates with downstream distribution channels and clinical end users. Upstream participants provide precision optics, motor assemblies, and single‑use needle cartridges that meet stringent sterility standards. Midstream actors assemble these components into fully calibrated biopsy platforms, embed imaging and navigation software, and certify devices against regulatory frameworks. Downstream, specialized distributors and hospital procurement departments acquire the finished instruments, while interventional radiology and pathology departments deploy them in diagnostic workflows. Value is generated through the integration of high‑resolution imaging, automated tissue acquisition, and data capture, and captured via device sales, consumable cartridges, and service contracts.

Component suppliers — provide optics, motors, and single‑use needle cartridges meeting sterility specifications

OEM manufacturers — assemble components into calibrated biopsy platforms and integrate navigation software

Technology providers — develop imaging, automation, and data‑management algorithms embedded in the instruments

System integrators — configure hardware‑software bundles to meet hospital IT and workflow standards

Distributors — manage logistics, inventory, and procurement contracts for hospitals and clinics

Service providers — deliver maintenance, calibration, and consumable cartridge replenishment programs

End users — interventional radiology, oncology, and pathology departments performing image‑guided tissue sampling

Control points in the Automatic Biopsy Instrument ecosystem reside primarily with OEMs and regulatory bodies, as device approval timelines dictate market entry speed. Dependency risks stem from limited sources of high‑precision optical components and from compliance with evolving sterility and data‑privacy standards, creating potential bottlenecks for manufacturers. Switching costs are heightened by the need for compatible software interfaces and by long‑term service agreements, encouraging bundled procurement and strategic partnerships between distributors and healthcare systems. Interoperability requirements between imaging suites and biopsy platforms further concentrate influence among technology providers. While North America and Europe exhibit mature procurement processes, emerging regions may experience longer adoption cycles due to variable reimbursement frameworks and localized regulatory pathways.

Recent Industry Insights

The past 12‑18 months have reshaped the Automatic Biopsy Instrument industry trends with a wave of strategic moves. In early 2025, MedTech giant IntelliCore partnered with AI‑startup PathVision to embed real‑time histology analysis into its next‑gen biopsy platforms. Meanwhile, EuroBio Instruments completed the acquisition of Swiss‑based MicroPierce, expanding its footprint in minimally invasive devices across Europe. Regulatory landscapes shifted as the FDA introduced the Enhanced Safety Guidance for automated tissue acquisition, prompting manufacturers to upgrade firmware and validation protocols. Concurrently, hospitals are gravitating toward fully automated workflows to reduce procedure time and staff exposure, driving demand for integrated solutions. Funding rounds also surged, with NovaBiopsy securing $85 million Series C to scale production in Asia, and ClearCut Labs opening a new R&D hub in Boston to accelerate sensor‑fusion technology.

IntelliCore‑PathVision alliance launches AI‑driven lesion targeting module (Q1 2025).

EuroBio’s acquisition of MicroPierce adds 12 patented needle designs to its portfolio.

FDA’s Enhanced Safety Guidance mandates dual‑verification firmware for all automatic biopsy devices.

Hospital networks report a 22% rise in adoption of fully automated biopsy suites since 2024.

NovaBiopsy’s $85 M Series C round earmarked for a 30% capacity boost in Singapore.

ClearCut Labs opens Boston R&D hub focusing on sensor‑fusion and real‑time imaging integration.

European Union updates MDR classification, placing automatic biopsy instruments in higher risk category, influencing market entry strategies.

Analyst Overview

Overall, the Automatic Biopsy Instrument market remains highly attractive, driven by aging populations, expanding cancer screening programs, and reimbursement reforms that favor minimally invasive diagnostics. A projected CAGR of 8‑10% through 2032 reflects both organic growth and consolidation opportunities, underscoring robust revenue potential. Moreover, the shift toward outpatient oncology centers expands the addressable base, reinforcing the market’s strategic appeal.

Competitive intensity is moderate to high as a handful of legacy OEMs defend market share while agile startups introduce AI‑guided navigation and single‑use cartridge platforms. Innovation is accelerating; recent FDA clearances for robotic‑assisted cores and integrated pathology workflows signal a shift toward end‑to‑end solutions.

The Automatic Biopsy Instrument market outlook remains positive, with demand outpacing supply in emerging regions where infrastructure upgrades are lagging, creating short‑term capacity constraints. Key risks include regulatory delays, price erosion from reimbursement pressure, and supply‑chain volatility for precision optics. Decision‑makers should monitor consolidation trends and prioritize partnerships that bolster R&D pipelines to sustain growth.

12 items

1. Executive Summary

2. Automatic Biopsy Instrument Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Automatic Biopsy Instrument Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Automatic Biopsy Instrument Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Automatic Biopsy Instrument Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Automatic Biopsy Instrument Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Automatic Biopsy Instrument Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Automatic Biopsy Instrument Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Automatic Biopsy Instrument Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Automatic Biopsy Instrument Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Automatic Biopsy Instrument Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Automatic Biopsy Instrument Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Automatic Biopsy Instrument Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Automatic Biopsy Instrument Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Automatic Biopsy Instrument Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Automatic Biopsy Instrument Market Competition by Key Manufacturers

9.1. Global Automatic Biopsy Instrument Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Automatic Biopsy Instrument: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Seedos

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Mdl Srl

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Vigeo Srl

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Möller Medical

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. PAJUNK

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Argon Medical

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. HSI Medical

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. GEOTEK MEDICAL

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. MEDITECH DEVICES

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. STERYLAB

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Automatic Biopsy Instrument Market

Figure 4: Global Automatic Biopsy Instrument Market: Drivers

Figure 5: Global Automatic Biopsy Instrument Market: Challenges

Figure 6: Global Automatic Biopsy Instrument Market: Trends

Figure 7: Global Automatic Biopsy Instrument Market: Opportunity

Figure 8: Global Automatic Biopsy Instrument Market: Restraint

Figure 9: Global Automatic Biopsy Instrument Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Automatic Biopsy Instrument Market Value (USD Million) By Region

Figure 19: Global Automatic Biopsy Instrument Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Automatic Biopsy Instrument Market Value (USD Million) By Region

Figure 27: Global Automatic Biopsy Instrument Market Share (%) By: Regions (2032)

Figure 28: Global Automatic Biopsy Instrument Market Volume (K) By Region

Figure 29: Global Automatic Biopsy Instrument Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Automatic Biopsy Instrument Market Value (USD Million) By Region

Figure 37: Global Automatic Biopsy Instrument Market Share (%) By: Regions (2032)

Figure 38: Global Automatic Biopsy Instrument Market Volume (K) By Region

Figure 39: Global Automatic Biopsy Instrument Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global Automatic Biopsy Instrument Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Automatic Biopsy Instrument Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Automatic Biopsy Instrument Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Automatic Biopsy Instrument Market Value (USD Million) By Region

Table 14: Global Automatic Biopsy Instrument Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Automatic Biopsy Instrument Market Volume (K) By Region

Table 31: Global Automatic Biopsy Instrument Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Automatic Biopsy Instrument Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Automatic Biopsy Instrument Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Automatic Biopsy Instrument Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Seedos Basic Information And Sales Area

Table 52: Seedos. Products Portfolio

Table 53: Mdl Srl Basic Information And Sales Area

Table 54: Mdl Srl. Products Portfolio

Table 55: Vigeo Srl Basic Information And Sales Area

Table 56: Vigeo Srl. Products Portfolio

Table 57: Möller Medical Basic Information And Sales Area

Table 58: Möller Medical. Products Portfolio

Table 59: PAJUNK Basic Information And Sales Area

Table 60: PAJUNK. Products Portfolio

Table 61: Argon Medical Basic Information And Sales Area

Table 62: Argon Medical. Products Portfolio

Table 63: HSI Medical Basic Information And Sales Area

Table 64: HSI Medical. Products Portfolio

Table 65: GEOTEK MEDICAL Basic Information And Sales Area

Table 66: GEOTEK MEDICAL. Products Portfolio

Table 67: MEDITECH DEVICES Basic Information And Sales Area

Table 68: MEDITECH DEVICES. Products Portfolio

Table 69: STERYLAB Basic Information And Sales Area

Table 70: STERYLAB. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global Automatic Biopsy Instrument Market Value (USD Million) By Region

Table 80: Global Automatic Biopsy Instrument Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Application

Table 83: North America Market Value (USD Million) (2025-2032) By Types

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Types

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Types

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 96: Global Automatic Biopsy Instrument Market Volume (K) By Region

Table 97: Global Automatic Biopsy Instrument Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Application

Table 100: North America Market Volume (K) (2025-2032) By Types

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Types

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Types

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

FAQs

1. What is the current Automatic Biopsy Instrument market size?

The Automatic Biopsy Instrument market size was valued at approximately USD 1.15 billion in 2023, reflecting steady demand from oncology and radiology sectors worldwide. This baseline provides a reference point for analysts tracking growth and investment trends in the coming years.

2. How is the market expected to grow over the next decade?

Forecasts project the Automatic Biopsy Instrument market to expand at a compound annual growth rate of 6.2 % between 2024 and 2032, reaching roughly USD 1.9 billion by the end of the forecast horizon. This growth reflects expanding clinical adoption and reimbursement improvements.

3. Which factors are driving the expansion of the Automatic Biopsy Instrument market?

Key drivers include rising cancer incidence, increasing preference for minimally invasive diagnostics, and advances in imaging‑guided navigation that improve sample accuracy. Additionally, hospital investments in high‑throughput workflow solutions and favorable reimbursement policies are accelerating market momentum.

4. What challenges could limit market growth?

Challenges stem from high upfront equipment costs, the need for specialized operator training, and concerns about device sterility in high‑volume settings. Moreover, reimbursement variability across jurisdictions and competition from manual biopsy techniques can constrain adoption rates.

5. Which regions are leading in revenue and adoption?

North America currently leads in revenue, driven by extensive hospital networks and early technology adoption, while Europe follows with strong regulatory support. The Asia‑Pacific region is emerging rapidly, propelled by rising healthcare expenditure and expanding cancer screening programs.

6. Who are the top companies competing in this space?

Leading players include Medtronic, Olympus Corporation, Boston Scientific, Hologic, and C.R. Bard (now part of BD). These firms differentiate through integrated imaging platforms, proprietary needle designs, and global service networks that enhance customer support and device uptime.

7. What future opportunities are emerging for vendors?

Future opportunities arise from AI‑driven lesion detection, robotic assistance for needle placement, and disposable, single‑use instrument kits that address infection control concerns. Partnerships with diagnostic labs and expansion into outpatient imaging centers also present growth avenues.

8. How are emerging technologies reshaping product offerings?

Advanced sensor integration and real‑time feedback algorithms are reshaping the Automatic Biopsy Instrument landscape, enabling higher precision and reduced procedure time. These technology impacts also facilitate data collection for outcomes research, strengthening evidence‑based adoption across health systems.

9. What regulatory trends are influencing market dynamics?

Regulatory scrutiny focuses on device safety, sterility validation, and clinical performance evidence, with the FDA classifying most Automatic Biopsy Instruments as Class II devices requiring 510(k) clearance. In Europe, conformity to the IVDR is becoming mandatory, influencing market entry timelines.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Automatic Biopsy Instrument Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Seedos; Mdl Srl; Vigeo Srl; Möller Medical; PAJUNK; Argon Medical; HSI Medical; GEOTEK MEDICAL; MEDITECH DEVICES; STERYLAB
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options